

Percent
100
80
60
40
20
Spleen Weight (g)
Mortality (%)
T and B cell Response
to Mitogen or Antigen
(% of normal)
Weight (g)
1.4
1.2
1.0
0.8
0.6
0.4
0.2
2
4
6
8
10
12
14
16
18
24
Weeks Post Infection

Figure 1.



Spleen weight < 0.25g = MAIDS
AVERAGE SPLEEN WEIGHT (g)
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
control Virus 0.25 0.75 1.25 1.75 2 3 4 5 6 7 8 10 12 14 16 21 28
control
TIME OF Vb ADMINISTRATION POST INFECTION (Days)

Figure 2.

Normal mouse spleen
MAIDS mouse spleen
Day 14 pi Vb treated mouse spleen

Figure 3.



*=Spleen weight at humane endpoint
AVERAGE SPLEEN WEIGHT (g)
1.2
1
0.8
0.6
0.4
0.2
0
Uninfected control
MAIDS infected control (10 weeks)
Day 14 Vb (10 weeks)
MAIDS infected control (20 weeks *)
Day 14 Vb (20 weeks)

Figure 4.



AVERAGE SPLEEN WEIGHT (g)
1.2
1
0.8
0.6
0.4
0.2
0
* = Spleen weight at humane endpoint
Uninfected control
MAIDS infected control (20 weeks*)
Day 14 Vb (20 weeks)
Rechallenge at 21 days post Vb (20 weeks*)
Rechallenge at 8 weeks post Vb (20 weeks*)

Figure 5.

18 JAN 2005




Figure 6.



Predicted outcome
Spleen cell transfer iv to recipient mice
Transfer ~10^7 cells
I
MAIDS
In vitro depletion of CD4+ spleen cells
Transfer ~10^7 cells
II
No MAIDS
Transfer ~10^7 cells
III
No MAIDS
10 weeks pi
Day 0
D 14 pi
D 15 pi
MAIDS virus (100ul i.p.)
Vb
Collect spleen cells for transfer
Donor protocol
Day 0
D 14 pi
D 15 pi
MAIDS virus (100ul i.p.)
Vb
Receive spleen cells
Euthanase dissect & weigh spleen
Recipient protocol

Figure 7.



AVERAGE SPLEEN WEIGHT (g)
0.6
0.5
0.4
0.3
0.2
0.1
0
Uninfected control
MAIDS infected control
Day 14 Vb control
Untreated donor spleen cells
Vb treated donor spleen cells
CD4+ depleted donor spleen cells

Figure 8.



in vivo CD8 depletion
Anti-CD8 mAb treatment
MAIDS
in vivo CD4 depletion
anti-CD4 mAb treatment
No MAIDS
Day 0
MAIDSvirus 100ul ip
Day 14
mAb injection 0.5 mg ip
Week 10
Euthanase dissect & weigh spleen
Predicted outcomes
Controls received no monoclonal antibody treatment

Figure 9.

18 JAN 2005




Figure 10.